Gentris is a leading global provider of applied clinical pharmacogenomic services (PGx). Government regulators continue to encourage and, in many cases, require companies to evaluate the possible link between genetic variation and the safety and efficacy of new drugs.

As pioneers in the field of PGx, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate PGx into their clinical drug development programs.

Pharmacogenomics is the use of a person's genetic profile to more accurately predict the safety, toxicity, and efficacy of drugs with the ultimate goal of improving an individual's treatment and prognosis.

Incorporating PGx enables an accelerated drug development process, resulting in more predictable responses to drug therapy and less frequent, less severe, adverse drug reactions. Applying PGx can also result in a significant reduction in clinical study costs.

Gentris is compliant with the FDA's stringent Good Laboratory Practice guidelines.

We have hundreds of standard operating procedures that ensure reproducibility in genetic testing, and proprietary processes.

Gentris provides a full range of GLP-compliant and CLIA-certified services for pharmaceutical and biotech companies plus clinical research organizations seeking to deliver safer and more effective drugs to the market.    View our entire portfolio